Skip to content

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS)

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02168816
Acronym
CRO-OSTEO
Enrollment
30
Registered
2014-06-20
Start date
2014-03-19
Completion date
2017-02-02
Last updated
2018-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteomyelitis

Keywords

Osteomyelitis, Diabetes, Foot Infection

Brief summary

The Infectious Diseases Society of America (IDSA) 2012 guidelines for the diagnosis and treatment of diabetic foot infections state that for the treatment of diabetic foot osteomyelitis No data support the superiority of any specific antibiotic agent or treatment strategy, route, or duration of therapy. Traditionally, osteomyelitis has been treated with a long course of intravenous antibiotics, generally six weeks. Oral antibiotics with high bioavailability and adequate bone penetration have been shown in published studies to be effective for the treatment of osteomyelitis. The investigators propose to conduct a prospective, single-center, randomized, open trial at Loyola University Medical Center (LUMC) comparing the efficacy of oral antibiotic therapy to intravenous (IV) antibiotic therapy for the treatment of diabetic foot osteomyelitis. The investigators hypothesize that oral antibiotic therapy is equivalent to IV antibiotic therapy. Bone/tissue cultures are obtained for all patients for clinical purposes and are sent to pathology for histologic examination and to the clinical microbiology laboratory for culture and susceptibility. Patients will receive six weeks of IV or oral antibiotic therapy depending upon their randomization group. Primary outcomes at six months clinical follow-up will include: (i) no evidence of bone infection and (ii) resolution of ulcer.

Detailed description

Currently, available literature is not adequate to determine the best agent, route, or duration of antibiotic therapy for the treatment of chronic osteomyelitis. The standard of therapy has been to treat patients with a parenteral antibiotic for four to six weeks. In a recent literature review by Spellberg et al. it was concluded that oral and parenteral antibiotic therapy have similar cure rates for the treatment of chronic osteomyelitis. Oral antibiotic therapy is associated with a lower risk to the patient due to avoiding the need of a central IV line. Additionally, oral therapy costs less than a course of IV antibiotics. Oral antibiotics with high bioavailability and good bone penetration include, fluoroquinolones, linezolid, trimethoprim/sulfamethoxazole (2 tabs bid), clindamycin and metronidazole. These antibiotics have been shown in recent studies to obtain levels in the bone that exceed the minimum inhibitory concentration (MIC) levels of the targeted organisms. According to the IDSA 2012 guidelines for the treatment of diabetic foot infections, the diagnosis of osteomyelitis can be made via plain radiographs or MRI imaging (more sensitive). A bone scan can be considered if an MRI cannot be done. The preferred method of diagnosis is by bone culture and histology. The guidelines also recommend surgical debridement to healthy tissue for diabetic foot infections followed by antibiotic therapy. The Purpose of this study is to compare the efficacy of oral antibiotic therapy with intravenous antibiotic therapy for the treatment of diabetic foot osteomyelitis following surgical debridement. They hypothesis is that oral antibiotic therapy is equivalent to intravenous antibiotic therapy for the treatment of diabetic foot osteomyelitis.

Interventions

DRUGIntravenous Antibacterial Agent

Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.

DRUGOral Antibacterial Agent

Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)

Sponsors

Loyola University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age and older * Diagnosis of Diabetes Mellitus (per past medical history documented in the patient medical record) * Foot osteomyelitis (distal to ankle) * Surgical debridement (in operating room)

Exclusion criteria

* Absolute neutrophil count (ANC) \< 500 * Pregnant or lactating patients * Patients with organisms resistant to oral therapy * Internal hardware * Definitive amputations (BKA) * Limb ischemia \[absent pedal pulses or ankle-brachial index (ABI) \< 0.5\]

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Bone InfectionSix MonthsSix months following completion of treatment, the researchers record evidence of bone infection for each participant. A negative diagnosis is made when there is (i) an absence of infection based on clinical examination and (ii) down-trending of inflammatory markers. Otherwise, a positive diagnosis is made.

Secondary

MeasureTime frameDescription
Number of Participants With Ulcer ResolutionSix MonthsSix months following completion of treatment, the researchers record whether each participant's ulcer has resolved.

Countries

United States

Participant flow

Recruitment details

Participants were recruited from March 2014 through February 2017 (36 months) from a tertiary care practice

Pre-assignment details

Prior to randomization, 16 participants were excluded because they tested positive for organisms that were resistant to oral antibiotic therapy. Additionally, one participant withdrew prior to randomization and one participant was excluded prior to randomization due to a definitive amputation.

Participants by arm

ArmCount
Intravenous Antibacterial Agent
Individuals in this arm were randomized to an intravenous antibacterial agent. They were not assigned to specific medications. Instead, individuals in this arm received an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy was usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
7
Oral Antibacterial Agent
Individuals in this arm were randomized to an oral antibacterial agent. They were not assigned to specific medications. Instead, individuals in this arm received an oral antibacterial agent as determined by their primary healthcare provider. This therapy was usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
5
Total12

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up22

Baseline characteristics

CharacteristicTotalIntravenous Antibacterial AgentOral Antibacterial Agent
Age, Continuous54.60 years56.18 years45.86 years
Comorbid Cancer
No
12 Participants7 Participants5 Participants
Comorbid Cancer
Yes
0 Participants0 Participants0 Participants
Comorbid Chronic Kidney Disease
No
11 Participants7 Participants4 Participants
Comorbid Chronic Kidney Disease
Yes
1 Participants0 Participants1 Participants
Comorbid Coronary Artery Disease
No
10 Participants6 Participants4 Participants
Comorbid Coronary Artery Disease
Yes
2 Participants1 Participants1 Participants
Comorbid Depression
No
12 Participants7 Participants5 Participants
Comorbid Depression
Yes
0 Participants0 Participants0 Participants
Comorbid Diabetes
No
0 Participants0 Participants0 Participants
Comorbid Diabetes
Yes
12 Participants7 Participants5 Participants
Comorbid Heart Disease
No
11 Participants7 Participants4 Participants
Comorbid Heart Disease
Yes
1 Participants0 Participants1 Participants
Comorbid Hyperlipidemia
No
6 Participants3 Participants3 Participants
Comorbid Hyperlipidemia
Yes
6 Participants4 Participants2 Participants
Comorbid Hypertension
No
4 Participants2 Participants2 Participants
Comorbid Hypertension
Yes
8 Participants5 Participants3 Participants
Comorbid Obesity
No
11 Participants6 Participants5 Participants
Comorbid Obesity
Yes
1 Participants1 Participants0 Participants
Comorbid Peripheral Vascular Disease
No
11 Participants6 Participants5 Participants
Comorbid Peripheral Vascular Disease
Yes
1 Participants1 Participants0 Participants
Comorbid Thyroid Disorder
No
12 Participants7 Participants5 Participants
Comorbid Thyroid Disorder
Yes
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants2 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants5 Participants4 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
History of Heart Attack
No
12 Participants7 Participants5 Participants
History of Heart Attack
Yes
0 Participants0 Participants0 Participants
History of Stroke
No
12 Participants7 Participants5 Participants
History of Stroke
Yes
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
3 Participants1 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants2 Participants0 Participants
Race (NIH/OMB)
White
7 Participants4 Participants3 Participants
Region of Enrollment
United States
12 participants7 participants5 participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
12 Participants7 Participants5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 70 / 5
other
Total, other adverse events
0 / 71 / 5
serious
Total, serious adverse events
0 / 70 / 5

Outcome results

Primary

Number of Participants With Bone Infection

Six months following completion of treatment, the researchers record evidence of bone infection for each participant. A negative diagnosis is made when there is (i) an absence of infection based on clinical examination and (ii) down-trending of inflammatory markers. Otherwise, a positive diagnosis is made.

Time frame: Six Months

Population: The analysis population comprises all randomized participants who had a six month follow-up appointment.

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Intravenous Antibacterial AgentNumber of Participants With Bone InfectionBone Infection Negative5 Participants
Intravenous Antibacterial AgentNumber of Participants With Bone InfectionBone Infection Positive0 Participants
Oral Antibacterial AgentNumber of Participants With Bone InfectionBone Infection Negative3 Participants
Oral Antibacterial AgentNumber of Participants With Bone InfectionBone Infection Positive0 Participants
Secondary

Number of Participants With Ulcer Resolution

Six months following completion of treatment, the researchers record whether each participant's ulcer has resolved.

Time frame: Six Months

Population: The analysis population comprises all randomized participants who had a six month follow-up appointment.

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Intravenous Antibacterial AgentNumber of Participants With Ulcer ResolutionResolved0 Participants
Intravenous Antibacterial AgentNumber of Participants With Ulcer ResolutionNot Resolved5 Participants
Oral Antibacterial AgentNumber of Participants With Ulcer ResolutionNot Resolved2 Participants
Oral Antibacterial AgentNumber of Participants With Ulcer ResolutionResolved1 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026